Myriad Genetics (MYGN) Cost of Revenue (2009 - 2026)

Myriad Genetics (MYGN) has 18 years of Cost of Revenue data on file, last reported at $62.8 million in Q1 2026.

• Cost of Revenue for Q1 2026 came in at $62.8 million, up 1.78% year-over-year; the trailing twelve-month figure through Mar 2026 was $258.1 million (down 8.21% YoY), and the FY2025 annual result was $247.9 million, down 12.74% from the prior year.
• Cost of Revenue was little changed at $62.8 million in Q1 2026 per MYGN's latest filing, from $63.0 million in the prior quarter.
• Over five years, Cost of Revenue peaked at $118.7 million in Q4 2022 and troughed at $48.0 million in Q1 2022.
• A 5-year average of $68.5 million and a median of $62.8 million in 2026 frame the typical range for Cost of Revenue.
• The sharpest annual moves came in 2022 and 2025: Cost of Revenue soared 192.73% in 2022, then slumped 31.22% in 2025.
• A 5-year view of Cost of Revenue shows it stood at $118.7 million in 2022, then slipped by 3.45% to $114.6 million in 2023, then slipped by 20.07% to $91.6 million in 2024, then tumbled by 31.22% to $63.0 million in 2025, then retreated by 0.32% to $62.8 million in 2026.
• Business Quant data shows MYGN's Cost of Revenue at $62.8 million in Q1 2026, $63.0 million in Q4 2025, and $71.0 million in Q3 2025.